Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Authors:

Abstract
Renal cell carcinoma (RCC) is the sixth most common cancer among men and the eighth most common cancer among women in the US, accounting for 4.2% of all incident cancer cases and 2.4% of all cancer deaths each year.1 Approximately 30% of patients with RCC present with either regional or distant metastases, and 20% of individuals who receive an initial diagnosis of localized disease will eventually develop regional or distant metastases.1-3 Clear cell RCC is the most common histologic subtype, representing approximately 80% of all RCCs.4

This publication has 25 references indexed in Scilit: